ClinicalTrials.gg
TerminatedNCT05053035Updated Jun 18, 2025Results posted

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

A Phase 2 interventional study of AL001 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Alector Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-18.

Sponsored by Alector Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sponsor is considering a subsequent study in ALS, potentially with different inclusion/exclusion criteria.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
271st of 307
5 · median 33
Started
2021
with 32 others
Phase 2
89 of 440
8 open now
Registered
301st of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 271st largest by enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2021, is one of 89 in phase 2, and was the 301st registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.

Read the detailed description

This is a phase 2 double-blind, placebo-controlled trial to test the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in participants with C9orf72-associated Amyotrophic Lateral Sclerosis.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation of C9orf72 mutation
  • Diagnosis of ALS by revised El Escorial criteria
  • Time since onset of muscle weakness due to ALS ≤36 months at the time of the Screening Visit
  • Slow Vital Capacity (VC) ≥50% of predicted capacity at the time of the Screening Visit
  • If taking riluzole, must be on a stable dose of riluzole for at least 30 days prior to the Screening Visit. Riluzole naive participants are allowed.
  • If taking edaravone, must have completed at least one cycle of edaravone prior to the Screening Visit and plan to continue edaravone during the study. Edaravone naive participants are allowed.
  • Females must not be pregnant, breastfeeding or planning to conceive within the study period. Males must agree to use acceptable
  • Capable of providing at the Screening visit and complying with study procedures throughout the study

Exclusion criteria

Exclusion Criteria:

  • , unstable, medical condition (other than ALS)
  • Clinically significant heart disease, liver disease or kidney disease
  • Cognitive impairment or dementia
  • Current uncontrolled hypertension
  • History of unresolved cancer
  • Any experimental gene therapy
  • Any experimental vaccine (any vaccine against COVID-19 either approved or administered under an Emergency Use Authorization is allowed)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    AL001

    AL001 every 4 weeks

    Drug: AL001

  • Placebo comparator
    Placebo

    Placebo every 4 weeks

    Drug: Placebo

Interventions

  • DrugAL001

    Administered via intravenous (IV) infusion

  • DrugPlacebo

    Administered via intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Evaluation of Safety and Tolerability of AL001 Measured by Number of Subjects With Adverse Events

    Count of participants with adverse events during the study treatment period

    Time frame: 24 weeks

  2. Immunogenicity of AL001

    Count of participants positive for Anti-drug Antibodies (ADAs) to AL001 at week 24

    Time frame: Week 24

  3. Pharmacokinetics (PK) of AL001 in Serum

    Concentration of AL001 in Serum at week 24

    Time frame: Week 24

  4. Pharmacokinetics (PK) of AL001 in CSF

    Concentration of AL001 in Cerebrospinal fluid (CSF) at week 24

    Time frame: Week 24

  5. Change From Baseline in Plasma Progranulin

    Evaluate the change from baseline to week 24 in plasma progranulin levels

    Time frame: 24 weeks

  6. Change From Baseline in CSF Progranulin

    Evaluate the change from baseline to week 24 in Cerebrospinal fluid (CSF) progranulin levels

    Time frame: 24 weeks

Secondary outcomes

  1. Change From Baseline in Plasma Neurofilament Light Chain

    Evaluate the change from baseline to week 24 in plasma neurofilament light chain levels

    Time frame: 24 weeks

  2. Change From Baseline in CSF Neurofilament Light Chain

    Evaluate change from baseline to week 24 in Cerebrospinal fluid (CSF) neurofilament light chain levels

    Time frame: 24 weeks

07

Results

Posted Jun 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneAL001Placebo
Started32
Completed22
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryEvaluation of Safety and Tolerability of AL001 Measured by Number of Subjects With Adverse Events

Count of participants with adverse events during the study treatment period

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Evaluation of Safety and Tolerability of AL001 Measured by Number of Subjects With Adverse Events
ParticipantsAL001Placebo
Evaluation of Safety and Tolerability of AL001 Measured by Number of Subjects With Adverse Events22
PrimaryImmunogenicity of AL001

Count of participants positive for Anti-drug Antibodies (ADAs) to AL001 at week 24

Time frame:
Week 24
Reported as:
Count of participants · Participants
Immunogenicity of AL001
ParticipantsAL001Placebo
Immunogenicity of AL00110
PrimaryPharmacokinetics (PK) of AL001 in Serum

Concentration of AL001 in Serum at week 24

Time frame:
Week 24
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) of AL001 in Serum
ng/mLAL001Placebo
Pharmacokinetics (PK) of AL001 in Serum705792.5 ± 87387.7916—
PrimaryPharmacokinetics (PK) of AL001 in CSF

Concentration of AL001 in Cerebrospinal fluid (CSF) at week 24

Time frame:
Week 24
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) of AL001 in CSF
ng/mLAL001Placebo
Pharmacokinetics (PK) of AL001 in CSF547.5 ± 395.2727—
PrimaryChange From Baseline in Plasma Progranulin

Evaluate the change from baseline to week 24 in plasma progranulin levels

Time frame:
24 weeks
Reported as:
Mean · ng/mL
Change From Baseline in Plasma Progranulin
ng/mLAL001Placebo
Change From Baseline in Plasma Progranulin175 ± 2.8284-24.4 ± 9.3338
PrimaryChange From Baseline in CSF Progranulin

Evaluate the change from baseline to week 24 in Cerebrospinal fluid (CSF) progranulin levels

Time frame:
24 weeks
Reported as:
Mean · ng/mL
Change From Baseline in CSF Progranulin
ng/mLAL001Placebo
Change From Baseline in CSF Progranulin2.865 ± 1.0677-0.385 ± 0.3323
SecondaryChange From Baseline in Plasma Neurofilament Light Chain

Evaluate the change from baseline to week 24 in plasma neurofilament light chain levels

Time frame:
24 weeks
Reported as:
Mean · pg/mL
Change From Baseline in Plasma Neurofilament Light Chain
pg/mLAL001Placebo
Change From Baseline in Plasma Neurofilament Light Chain-0.35 ± 3.32341.9 ± 2.8284
SecondaryChange From Baseline in CSF Neurofilament Light Chain

Evaluate change from baseline to week 24 in Cerebrospinal fluid (CSF) neurofilament light chain levels

Time frame:
24 weeks
Reported as:
Mean · pg/mL
Change From Baseline in CSF Neurofilament Light Chain
pg/mLAL001Placebo
Change From Baseline in CSF Neurofilament Light Chain995.5 ± 95.4594-1250.5 ± 825.1936

Adverse events

Collected over 32 Weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AL0010/3 (0%)0/3 (0%)2/3 (66.7%)
Placebo0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventAL001Placebo
Post lumbar puncture syndromeInjury, poisoning and procedural complications2/31/2
ConstipationGastrointestinal disorders0/31/2
DiarrheaGastrointestinal disorders0/31/2
NauseaGastrointestinal disorders0/31/2
Catheter site irritationGeneral disorders0/31/2
FatigueGeneral disorders0/31/2
Medical device site hemorrhageGeneral disorders0/31/2
PainGeneral disorders0/31/2
PyrexiaGeneral disorders0/31/2
Urinary tract infectionInfections and infestations0/31/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AL001PlaceboTotal
<=18 years000
Between 18 and 65 years224
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)AL001PlaceboTotal
Female123
Male202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AL001PlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White325
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)AL001PlaceboTotal
United States325
08

Study locations

3 sites
  • University of South Florida
    Tampa, Florida 33612, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Oct 2022, 13 months.

Results were first posted in Jun 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2021
First posted
Sep 22, 2021
StartActual
Sep 2, 2021
Primary completionActual
Oct 28, 2022
CompletionActual
Oct 28, 2022
Results first posted
Jun 18, 2025
Last update
Jun 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05053035
Lead sponsor
Alector Inc.
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Sep 2, 2021
Primary completion
Oct 28, 2022
Completion
Oct 28, 2022
Results posted
Jun 18, 2025
Last update
Jun 18, 2025

Study contacts

Sabrina Paganoni, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion